Previous 10 | Next 10 |
Despite supply chain disruptions and labor shortages, the pharma industry is well-positioned to continue growing due to the increasing medical needs of an aging population and advancements in treating chronic diseases. Therefore, amid current market volatility, we believe it could be wise to ...
Featuring in the Bloomberg Gender-Equality Index (GEI) for the fifth year in a row, Dr. Reddy’s is the only Indian pharma company from among seven Indian companies to be listed in the 2022 index Included in S&P Global’s Sustainability Yearbook for a second ...
Prestige BioPharma and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for...
Prestige BioPharma and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for...
Dr. Reddy’s Laboratories (NYSE:RDY) announces the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical. According to IQVIA Health, the brand and generic had U.S. sales of ~$51M for tw...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine E...
Prestige BioPharma and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige Bio's proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige Bio's t...
Dr. Reddy’s Laboratories (NYSE:RDY) announces the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of FDA approved Diovan (valsartan) Tablets. The Diovan brand and generic market had U.S. sales of ~$150M for twelve months ending in October 2021 according to IQ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan&...
Prestige BioPharma Ltd. (KRX: 950210) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclus...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...